$VNDA
Vanda Pharmaceuticals Inc.

2016 Q1 Form 10-K Financial Statement

#000119312516461076 Filed on February 12, 2016

View on sec.gov

Income Statement

Concept 2016 Q1 2015 2014 Q4
Revenue $33.26M $109.9M $15.37M
YoY Change 50.17% 119.16% 75.0%
Cost Of Revenue $5.956M $23.46M $680.0K
YoY Change 18.76% 1382.12%
Gross Profit $24.36M $86.46M $14.69M
YoY Change 87.54% 78.0%
Gross Profit Margin 73.25% 78.66% 95.56%
Selling, General & Admin $29.29M $84.53M $17.32M
YoY Change 55.75% -0.13% 74.42%
% of Gross Profit 120.22% 97.77% 117.92%
Research & Development $7.548M $29.15M $4.750M
YoY Change 68.56% 51.56% -24.24%
% of Gross Profit 30.98% 33.71% 32.34%
Depreciation & Amortization $219.0K $582.0K $700.0K
YoY Change 56.43% 9.81% 40.0%
% of Gross Profit 0.9% 0.67% 4.77%
Operating Expenses $36.84M $113.7M $22.62M
YoY Change 58.21% 9.44% 36.51%
Operating Profit -$12.48M -$40.19M $69.69M
YoY Change 21.2% -300.3% -994.53%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net $120.0K $300.0K $30.00K
YoY Change 71.43% 200.0% -25.0%
Pretax Income -$12.36M -$39.87M $69.72M
YoY Change 20.92% -297.49% -999.61%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income 0.0%
Net Earnings -$12.36M -$39.87M $69.72M
YoY Change 20.91% -297.49% -999.95%
Net Earnings / Revenue -37.15% -36.27% 453.6%
Basic Earnings Per Share -$0.94 $1.85
Diluted Earnings Per Share -$286.8K -$0.94 $1.77
COMMON SHARES
Basic Shares Outstanding 43.10M shares 42.25M shares 33.90M shares
Diluted Shares Outstanding 42.25M shares

Balance Sheet

Concept 2016 Q1 2015 2014 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $138.3M $143.2M $129.8M
YoY Change 2.98% 10.32% -0.41%
Cash & Equivalents $38.74M $50.80M $60.90M
Short-Term Investments $99.59M $92.30M $68.92M
Other Short-Term Assets $6.500M $5.700M $154.0K
YoY Change 1906.17% 83.87% 20.31%
Inventory $938.0K $1.300M $5.170M
Prepaid Expenses
Receivables $16.68M $16.30M $3.654M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $162.4M $166.5M $141.7M
YoY Change 0.17% 17.5% 4.51%
LONG-TERM ASSETS
Property, Plant & Equipment $4.351M $4.600M $2.437M
YoY Change 41.27% 91.67% 10.87%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $4.100M $3.200M $28.00K
YoY Change 412.5% 300.0% -94.4%
Total Long-Term Assets $44.29M $46.60M $29.97M
YoY Change -13.95% 55.33% 287.51%
TOTAL ASSETS
Total Short-Term Assets $162.4M $166.5M $141.7M
Total Long-Term Assets $44.29M $46.60M $29.97M
Total Assets $206.7M $213.1M $171.7M
YoY Change -3.23% 24.11% 19.78%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $5.500M $5.300M $835.0K
YoY Change 269.13% 278.57% 26.32%
Accrued Expenses $49.50M $46.00M $6.951M
YoY Change 63.37% 630.16% 34.19%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $55.04M $51.30M $7.786M
YoY Change 73.14% 557.69% -76.3%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $3.688M $28.70M $3.101M
YoY Change -15.76% 825.81% -95.33%
Total Long-Term Liabilities $3.688M $28.70M $3.101M
YoY Change -15.76% 825.81% -95.33%
TOTAL LIABILITIES
Total Short-Term Liabilities $55.04M $51.30M $7.786M
Total Long-Term Liabilities $3.688M $28.70M $3.101M
Total Liabilities $83.73M $80.00M $10.89M
YoY Change 36.88% 633.94% -89.03%
SHAREHOLDERS EQUITY
Retained Earnings -$340.2M -$288.0M
YoY Change 14.08% -6.55%
Common Stock $463.1M $448.8M
YoY Change 2.77% 27.4%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $123.0M $133.0M $160.8M
YoY Change
Total Liabilities & Shareholders Equity $206.7M $213.1M $171.7M
YoY Change -3.23% 24.11% 19.78%

Cashflow Statement

Concept 2016 Q1 2015 2014 Q4
OPERATING ACTIVITIES
Net Income -$12.36M -$39.87M $69.72M
YoY Change 20.91% -297.49% -999.95%
Depreciation, Depletion And Amortization $219.0K $582.0K $700.0K
YoY Change 56.43% 9.81% 40.0%
Cash From Operating Activities -$4.900M $12.40M -$13.40M
YoY Change -187.5% -115.2% 9.84%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $2.527M -$400.0K
YoY Change -100.0% 228.61% 300.0%
Acquisitions
YoY Change
Other Investing Activities -$7.200M -$24.10M -$28.20M
YoY Change -78.05% 630.3% -57.01%
Cash From Investing Activities -$7.200M -$26.60M -$28.50M
YoY Change -78.57% 121.67% -56.62%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $62.30M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 4.100M 87.50M
YoY Change -100.0% -95.43% 17400.0%
NET CHANGE
Cash From Operating Activities -4.900M 12.40M -13.40M
Cash From Investing Activities -7.200M -26.60M -28.50M
Cash From Financing Activities 0.000 4.100M 87.50M
Net Change In Cash -12.10M -10.10M 45.60M
YoY Change -56.94% 158.97% -158.91%
FREE CASH FLOW
Cash From Operating Activities -$4.900M $12.40M -$13.40M
Capital Expenditures $0.00 $2.527M -$400.0K
Free Cash Flow -$4.900M $9.873M -$13.00M
YoY Change -201.72% -111.99% 7.44%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2013Q3 us-gaap Sale Of Stock Price Per Share
SaleOfStockPricePerShare
11.14
CY2014Q4 us-gaap Sale Of Stock Price Per Share
SaleOfStockPricePerShare
11.60
CY2016Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
43102957 shares
CY2015Q2 dei Entity Public Float
EntityPublicFloat
525700000
CY2012Q4 us-gaap Deferred Revenue
DeferredRevenue
117064000
CY2012Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
133271000
CY2012Q4 us-gaap Stockholders Equity
StockholdersEquity
9905000
CY2012Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
88772000
CY2013Q4 us-gaap Deferred Revenue
DeferredRevenue
90275000
CY2013Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
141150000
CY2013Q4 us-gaap Stockholders Equity
StockholdersEquity
44124000
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
64764000
CY2014Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2014Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000 shares
CY2014Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
41486361 shares
CY2014Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000 shares
CY2014Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2014Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
41486361 shares
CY2014Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2014Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2014Q4 us-gaap Liabilities Current
LiabilitiesCurrent
7786000
CY2014Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
388000
CY2014Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1733000
CY2014Q4 us-gaap Liabilities
Liabilities
10887000
CY2014Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
7291000
CY2014Q4 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
602000
CY2014Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
9217000
CY2014Q4 us-gaap Common Stock Value
CommonStockValue
41000
CY2014Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
448744000
CY2014Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
3101000
CY2014Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
16000
CY2014Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2014Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
128890000
CY2014Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
2522000
CY2014Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2014Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
2020000
CY2014Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-287984000
CY2014Q4 us-gaap Deferred Tax Liabilities Other
DeferredTaxLiabilitiesOther
6000
CY2014Q4 us-gaap Stockholders Equity
StockholdersEquity
160817000
CY2014Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
171704000
CY2014Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
6000
CY2014Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
68921000
CY2014Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
3394000
CY2014Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits
17160000
CY2014Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2437000
CY2014Q4 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Inventory
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory
2960000
CY2014Q4 us-gaap Assets Current
AssetsCurrent
141730000
CY2014Q4 us-gaap Other Assets Current
OtherAssetsCurrent
154000
CY2014Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
2302000
CY2014Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
198000
CY2014Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
532000
CY2014Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
35941000
CY2014Q4 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Intangibles
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
15940000
CY2014Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
26724000
CY2014Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Domestic
DeferredTaxAssetsOperatingLossCarryforwardsDomestic
73626000
CY2014Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
60901000
CY2014Q4 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Assets Prepaid Expense And Other Assets
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets
91000
CY2014Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
1326000
CY2014Q4 us-gaap Assets
Assets
171704000
CY2014Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
128896000
CY2014Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Other
DeferredTaxAssetsTaxDeferredExpenseOther
806000
CY2014Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3084000
CY2014Q4 us-gaap Deferred Costs Current And Noncurrent
DeferredCostsCurrentAndNoncurrent
252000
CY2014Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
3654000
CY2014Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
4170000
CY2014Q4 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
800000
CY2014Q4 us-gaap Prepaid Insurance
PrepaidInsurance
270000
CY2014Q4 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Assets
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets
18991000
CY2014Q4 us-gaap Inventory Net
InventoryNet
5170000
CY2014Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
68921000
CY2014Q4 vnda Deferred Tax Assets Liabilities Before Valuation Allowance Net
DeferredTaxAssetsLiabilitiesBeforeValuationAllowanceNet
128890000
CY2014Q4 vnda Accrued Research And Development Expense
AccruedResearchAndDevelopmentExpense
1759000
CY2014Q4 vnda Deferred Tax Assets Tax Credit Carryforwards Research And Other
DeferredTaxAssetsTaxCreditCarryforwardsResearchAndOther
36772000
CY2014Q4 vnda Prepaid Manufacturing Costs
PrepaidManufacturingCosts
358000
CY2014Q4 vnda Accrued Government And Other Rebates Current
AccruedGovernmentAndOtherRebatesCurrent
495000
CY2014Q4 vnda Inventory And Other Non Current
InventoryAndOtherNonCurrent
813000
CY2015Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2015Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000 shares
CY2015Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
42815291 shares
CY2015Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000 shares
CY2015Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2015Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
42815291 shares
CY2015Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2015Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2015Q4 us-gaap Liabilities Current
LiabilitiesCurrent
51317000
CY2015Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
468000
CY2015Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2313000
CY2015Q4 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
1616000
CY2015Q4 us-gaap Liabilities
Liabilities
80023000
CY2015Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
15767000
CY2015Q4 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
5429000
CY2015Q4 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
5328000
CY2015Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
22189000
CY2015Q4 us-gaap Common Stock Value
CommonStockValue
43000
CY2015Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
460794000
CY2015Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
1538000
CY2015Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
3706000
CY2015Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
39000
CY2015Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
13315000
CY2015Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2015Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
139037000
CY2015Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
5088000
CY2015Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2015Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1684000
CY2015Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
1576000
CY2015Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-327849000
CY2015Q4 us-gaap Deferred Tax Liabilities Other
DeferredTaxLiabilitiesOther
1100000
CY2015Q4 us-gaap Stockholders Equity
StockholdersEquity
133027000
CY2015Q4 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
1656000
CY2015Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
213050000
CY2015Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
1100000
CY2015Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
1500000
CY2015Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
92337000
CY2015Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
1294000
CY2015Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits
12919000
CY2015Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4570000
CY2015Q4 us-gaap Assets Current
AssetsCurrent
166547000
CY2015Q4 us-gaap Other Assets Current
OtherAssetsCurrent
210000
CY2015Q4 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
232600000
CY2015Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
1721000
CY2015Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
4763000
CY2015Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
1721000
CY2015Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
1443000
CY2015Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
60941000
CY2015Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
38752000
CY2015Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Domestic
DeferredTaxAssetsOperatingLossCarryforwardsDomestic
86640000
CY2015Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
50843000
CY2015Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
1721000
CY2015Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
10933000
CY2015Q4 us-gaap Assets
Assets
213050000
CY2015Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
140137000
CY2015Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Other
DeferredTaxAssetsTaxDeferredExpenseOther
802000
CY2015Q4 us-gaap Finite Lived Intangible Assets Amortization Expense After Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
20935000
CY2015Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5742000
CY2015Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
16331000
CY2015Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
6883000
CY2015Q4 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
800000
CY2015Q4 us-gaap Prepaid Insurance
PrepaidInsurance
423000
CY2015Q4 us-gaap Inventory Net
InventoryNet
1294000
CY2015Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
92337000
CY2015Q4 us-gaap Inventory Noncurrent
InventoryNoncurrent
2496000
CY2015Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
1721000
CY2015Q4 vnda Number Of Stock Incentive Plans
NumberOfStockIncentivePlans
2 EquityPlan
CY2015Q4 vnda Inventory Raw Materials Net Of Reserves Non Current
InventoryRawMaterialsNetOfReservesNonCurrent
127000
CY2015Q4 vnda Deferred Tax Assets Liabilities Before Valuation Allowance Net
DeferredTaxAssetsLiabilitiesBeforeValuationAllowanceNet
139037000
CY2015Q4 vnda Accrued Research And Development Expense
AccruedResearchAndDevelopmentExpense
3199000
CY2015Q4 vnda Operating Loss Carryforwards Excess Windfall Benefits Generated From Stock Options
OperatingLossCarryforwardsExcessWindfallBenefitsGeneratedFromStockOptions
6500000
CY2015Q4 vnda Deferred Tax Assets Tax Credit Carryforwards Research And Other
DeferredTaxAssetsTaxCreditCarryforwardsResearchAndOther
38333000
CY2015Q4 vnda Inventory Work In Process Net Of Reserves Non Current
InventoryWorkInProcessNetOfReservesNonCurrent
2369000
CY2015Q4 vnda Milestone Obligation Under License Agreement
MilestoneObligationUnderLicenseAgreement
25000000
CY2015Q4 vnda Prepaid Manufacturing Costs
PrepaidManufacturingCosts
346000
CY2015Q4 vnda Accrued Government And Other Rebates Current
AccruedGovernmentAndOtherRebatesCurrent
35550000
CY2015Q4 vnda Inventory And Other Non Current
InventoryAndOtherNonCurrent
3181000
CY2013Q3 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
4680000 shares
CY2013Q3 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
48500000
CY2014Q4 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
5750000 shares
CY2014Q4 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
62300000
CY2013 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y11D
CY2013 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
-0.040 pure
CY2013 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4409811 shares
CY2013 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0.439 pure
CY2013 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
30351353 shares
CY2013 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000 pure
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0159 pure
CY2013 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-39592000
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
6.10
CY2013 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
0.000 pure
CY2013 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.69
CY2013 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
-0.003 pure
CY2013 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Other
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
-0.015 pure
CY2013 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
30351353 shares
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
0.65 pure
CY2013 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.69
CY2013 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.012 pure
CY2013 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
-0.011 pure
CY2013 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
-0.340 pure
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00 pure
CY2013 us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
-155000
CY2013 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
65598000
CY2013 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-21044000
CY2013 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
176000
CY2013 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
1550000
CY2013 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
48505000
CY2013 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5404000
CY2013 us-gaap Licenses Revenue
LicensesRevenue
26789000
CY2013 us-gaap Operating Income Loss
OperatingIncomeLoss
-21200000
CY2013 us-gaap Revenues
Revenues
33879000
CY2013 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
863000
CY2013 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
196000
CY2013 us-gaap Other Income
OtherIncome
145000
CY2013 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1264000
CY2013 us-gaap Net Income Loss
NetIncomeLoss
-21055000
CY2013 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-104000
CY2013 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
11000
CY2013 us-gaap Royalty Revenue
RoyaltyRevenue
7090000
CY2013 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax
11000
CY2013 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
48505000
CY2013 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
31499000
CY2013 us-gaap Depreciation
Depreciation
432000
CY2013 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
49859000
CY2013 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1495000
CY2013 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2013 us-gaap Advertising Expense
AdvertisingExpense
0
CY2013 us-gaap Other Comprehensive Income Loss Tax
OtherComprehensiveIncomeLossTax
0
CY2013 us-gaap Noncash Or Part Noncash Acquisition Fixed Assets Acquired1
NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1
106000
CY2013 us-gaap Employee Service Share Based Compensation Cash Received From Exercise Of Stock Options
EmployeeServiceShareBasedCompensationCashReceivedFromExerciseOfStockOptions
1550000
CY2013 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
261000
CY2013 us-gaap Costs And Expenses
CostsAndExpenses
55079000
CY2013 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-24008000
CY2013 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
1100000
CY2013 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
196000
CY2013 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5404000
CY2013 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
200000
CY2013 us-gaap Share Based Compensation
ShareBasedCompensation
5404000
CY2013 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
25082000
CY2013 us-gaap Deferred Revenue Revenue Recognized
DeferredRevenueRevenueRecognized
26789000
CY2013 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-34275000
CY2013 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
28502000
CY2013 vnda Deferred Tax Assets Valuation Allowance Increase
DeferredTaxAssetsValuationAllowanceIncrease
22998000
CY2013 vnda Effective Income Tax Rate Reconciliation Effective Tax Rate Adjustment
EffectiveIncomeTaxRateReconciliationEffectiveTaxRateAdjustment
0.185 pure
CY2013 vnda Deferred Tax Assets Valuation Allowance Decrease
DeferredTaxAssetsValuationAllowanceDecrease
15119000
CY2013 vnda Deferred Revenue Recognized
DeferredRevenueRecognized
-26789000
CY2013 vnda Effective Income Tax Rate Reconciliation Tax Credits Orphan Drug
EffectiveIncomeTaxRateReconciliationTaxCreditsOrphanDrug
-0.227 pure
CY2014 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y10M24D
CY2014 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
1912560 shares
CY2014 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.072 pure
CY2014 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3524656 shares
CY2014 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.597 pure
CY2014 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
34774163 shares
CY2014 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000 pure
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0173 pure
CY2014 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-81554000
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
6.99
CY2014 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
0.000 pure
CY2014 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.58
CY2014 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
0.048 pure
CY2014 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Other
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
0.028 pure
CY2014 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
36686723 shares
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
0.62 pure
CY2014 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.55
CY2014 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.011 pure
CY2014 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.013 pure
CY2014 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.340 pure
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00 pure
CY2014 us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
-174000
CY2014 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
93343000
CY2014 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
20181000
CY2014 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
769000
CY2014 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
2852000
CY2014 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
62313000
CY2014 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5878000
CY2014 us-gaap Licenses Revenue
LicensesRevenue
30746000
CY2014 us-gaap Operating Income Loss
OperatingIncomeLoss
20062000
CY2014 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
2210000
CY2014 us-gaap Revenues
Revenues
50157000
CY2014 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
1623000
CY2014 us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
-245000
CY2014 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
12909000
CY2014 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
436000
CY2014 us-gaap Other Income
OtherIncome
124000
CY2014 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
318000
CY2014 us-gaap Gain Loss Related To Litigation Settlement
GainLossRelatedToLitigationSettlement
77616000
CY2014 us-gaap Net Income Loss
NetIncomeLoss
20186000
CY2014 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-239000
CY2014 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-5000
CY2014 us-gaap Royalty Revenue
RoyaltyRevenue
6502000
CY2014 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
8000000
CY2014 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax
-5000
CY2014 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
62313000
CY2014 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
80882000
CY2014 us-gaap Depreciation
Depreciation
530000
CY2014 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
89728000
CY2014 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
2254000
CY2014 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2014 us-gaap Advertising Expense
AdvertisingExpense
5000000
CY2014 us-gaap Other Comprehensive Income Loss Tax
OtherComprehensiveIncomeLossTax
0
CY2014 us-gaap Employee Service Share Based Compensation Cash Received From Exercise Of Stock Options
EmployeeServiceShareBasedCompensationCashReceivedFromExerciseOfStockOptions
2851000
CY2014 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
1029000
CY2014 us-gaap Costs And Expenses
CostsAndExpenses
30095000
CY2014 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-3863000
CY2014 us-gaap Noncash Or Part Noncash Acquisition Inventory Acquired1
NoncashOrPartNoncashAcquisitionInventoryAcquired1
2960000
CY2014 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
1700000
CY2014 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
436000
CY2014 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5878000
CY2014 us-gaap Proceeds From Sale Of Available For Sale Securities
ProceedsFromSaleOfAvailableForSaleSecurities
8948000
CY2014 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
200000
CY2014 us-gaap Share Based Compensation
ShareBasedCompensation
5878000
CY2014 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
84644000
CY2014 us-gaap Deferred Revenue Revenue Recognized
DeferredRevenueRevenueRecognized
30746000
CY2014 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-12037000
CY2014 us-gaap Cost Of Goods Sold
CostOfGoodsSold
1583000
CY2014 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
19230000
CY2014 vnda Business Acquisition Prepaid Consideration
BusinessAcquisitionPrepaidConsideration
91000
CY2014 vnda Deferred Tax Assets Valuation Allowance Increase
DeferredTaxAssetsValuationAllowanceIncrease
27893000
CY2014 vnda Stock Issued During Period Value Settlement Agreement
StockIssuedDuringPeriodValueSettlementAgreement
25905000
CY2014 vnda Effective Income Tax Rate Reconciliation Effective Tax Rate Adjustment
EffectiveIncomeTaxRateReconciliationEffectiveTaxRateAdjustment
0.000 pure
CY2014 vnda Deferred Tax Assets Valuation Allowance Decrease
DeferredTaxAssetsValuationAllowanceDecrease
40153000
CY2014 vnda Deferred Revenue Recognized
DeferredRevenueRecognized
-30572000
CY2014 vnda Increase Decrease In Accrued Government And Other Rebates
IncreaseDecreaseInAccruedGovernmentAndOtherRebates
495000
CY2014 vnda Effective Income Tax Rate Reconciliation Tax Credits Orphan Drug
EffectiveIncomeTaxRateReconciliationTaxCreditsOrphanDrug
0.085 pure
CY2014 vnda Intangible Asset Related To Reacquired Right
IntangibleAssetRelatedToReacquiredRight
-15940000
CY2015 dei Document Type
DocumentType
10-K
CY2015 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2015 dei Trading Symbol
TradingSymbol
VNDA
CY2015 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2015 dei Entity Central Index Key
EntityCentralIndexKey
0001347178
CY2015 dei Document Period End Date
DocumentPeriodEndDate
2015-12-31
CY2015 us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<div> <p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%; MARGIN-TOP: 12px"> <font style="FONT-FAMILY: Times New Roman" size="2"><b><i>Reclassifications</i></b></font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2">Certain reclassifications have been made to prior year amounts to conform with current year classifications.</font></p> </div>
CY2015 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
-0.001 pure
CY2015 dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
CY2015 us-gaap Finite Lived Intangible Assets Amortization Method
FiniteLivedIntangibleAssetsAmortizationMethod
Straight-line basis
CY2015 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5660199 shares
CY2015 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2015 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y
CY2015 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2015 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div> <p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%; MARGIN-TOP: 12px"> <font style="FONT-FAMILY: Times New Roman" size="2"><b><i>Concentrations of credit risk</i></b></font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2">Financial instruments, which potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents and marketable securities. The Company places its cash, cash equivalents and marketable securities with highly-rated financial institutions. At December&#xA0;31, 2015, the Company maintained all of its cash, cash equivalents and marketable securities in two financial institutions. Deposits held with these institutions may exceed the amount of insurance provided on such deposits. Generally, these deposits may be redeemed upon demand, and the Company believes there is minimal risk of losses on such balances.</font></p> </div>
CY2015 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.254 pure
CY2015 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
42250254 shares
CY2015 us-gaap Defined Contribution Plan Maximum Annual Contributions Per Employee Percent
DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent
0.06 pure
CY2015 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000 pure
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0167 pure
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
P4Y
CY2015 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
12449000
CY2015 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
11.74
CY2015 dei Entity Registrant Name
EntityRegistrantName
Vanda Pharmaceuticals Inc.
CY2015 dei Amendment Flag
AmendmentFlag
false
CY2015 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1 Segment
CY2015 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
-0.051 pure
CY2015 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.94
CY2015 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%; MARGIN-TOP: 6px"> <font style="FONT-FAMILY: Times New Roman" size="2"><b><i>Use of Estimates</i></b></font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates that affect the reported amounts of assets and liabilities at the date of the financial statements, disclosure of contingent assets and liabilities, and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.</font></p> </div>
CY2015 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2015
CY2015 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
-0.003 pure
CY2015 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Other
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
-0.001 pure
CY2015 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
42250254 shares
CY2015 us-gaap Defined Contribution Plan Employer Matching Contribution Percent Of Match
DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
0.50 pure
CY2015 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
0.60 pure
CY2015 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.94
CY2015 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.057 pure
CY2015 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.015 pure
CY2015 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.350 pure
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00 pure
CY2015 us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
-677000
CY2015 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
193111000
CY2015 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-39842000
CY2015 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2527000
CY2015 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
4374000
CY2015 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
7961000
CY2015 us-gaap Operating Income Loss
OperatingIncomeLoss
-40185000
CY2015 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-387000
CY2015 us-gaap Revenues
Revenues
109925000
CY2015 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
12677000
CY2015 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
109925000
CY2015 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
283000
CY2015 us-gaap Other Income
OtherIncome
320000
CY2015 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2558000
CY2015 us-gaap Net Income Loss
NetIncomeLoss
-39865000
CY2015 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-657000
CY2015 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
23000
CY2015 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax
23000
CY2015 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
168041000
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
1800000
CY2015 us-gaap Depreciation
Depreciation
582000
CY2015 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
4091000
CY2015 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
12972000
CY2015 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2015 us-gaap Advertising Expense
AdvertisingExpense
3400000
CY2015 us-gaap Other Comprehensive Income Loss Tax
OtherComprehensiveIncomeLossTax
0
CY2015 us-gaap Noncash Or Part Noncash Acquisition Fixed Assets Acquired1
NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1
187000
CY2015 us-gaap Employee Service Share Based Compensation Cash Received From Exercise Of Stock Options
EmployeeServiceShareBasedCompensationCashReceivedFromExerciseOfStockOptions
4374000
CY2015 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
9432000
CY2015 us-gaap Noncash Or Part Noncash Acquisition Net Nonmonetary Assets Acquired Liabilities Assumed1
NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1
25000000
CY2015 us-gaap Costs And Expenses
CostsAndExpenses
150110000
CY2015 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-10058000
CY2015 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
1900000
CY2015 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
283000
CY2015 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7961000
CY2015 us-gaap Proceeds From Sale Of Available For Sale Securities
ProceedsFromSaleOfAvailableForSaleSecurities
999000
CY2015 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
300000
CY2015 us-gaap Share Based Compensation
ShareBasedCompensation
7961000
CY2015 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
84531000
CY2015 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-26598000
CY2015 us-gaap Cost Of Goods Sold
CostOfGoodsSold
23462000
CY2015 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
29145000
CY2015 vnda Share Based Compensation Option Awards Contractual Term
ShareBasedCompensationOptionAwardsContractualTerm
P10Y
CY2015 vnda Operating Loss Carryforwards Beginning Expiration Year
OperatingLossCarryforwardsBeginningExpirationYear
2028
CY2015 vnda Share Based Compensation Arrangement By Share Based Payment Award Remaining Percentage Of Share Subject To Option Awards
ShareBasedCompensationArrangementByShareBasedPaymentAwardRemainingPercentageOfShareSubjectToOptionAwards
0.75 pure
CY2015 vnda Share Based Compensation Arrangement By Share Based Payment Annual Award Vesting Period Directors
ShareBasedCompensationArrangementByShareBasedPaymentAnnualAwardVestingPeriodDirectors
P1Y
CY2015 vnda Deferred Tax Assets Valuation Allowance Increase
DeferredTaxAssetsValuationAllowanceIncrease
17002000
CY2015 vnda Percentage Of Responsibility For Patients Cost Of Branded Prescription Under Medicare Part D
PercentageOfResponsibilityForPatientsCostOfBrandedPrescriptionUnderMedicarePartD
0.50 pure
CY2015 vnda Tax Credit Carryforward Beginning Expiration Year
TaxCreditCarryforwardBeginningExpirationYear
2024
CY2015 vnda Percentage Of Future Sublicense Fees Payable
PercentageOfFutureSublicenseFeesPayable
Mid-twenties
CY2014Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.64
CY2014Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-21606000
CY2015 vnda Share Based Compensation Arrangement By Share Based Payment Award Percentage Of Share Subject To Option Awards
ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfShareSubjectToOptionAwards
0.25 pure
CY2015 vnda Effective Income Tax Rate Reconciliation Effective Tax Rate Adjustment
EffectiveIncomeTaxRateReconciliationEffectiveTaxRateAdjustment
-0.014 pure
CY2015 vnda Deferred Tax Assets Valuation Allowance Decrease
DeferredTaxAssetsValuationAllowanceDecrease
6855000
CY2015 vnda Share Based Compensation Arrangement By Share Based Payment Award Initial Vesting Period Directors
ShareBasedCompensationArrangementByShareBasedPaymentAwardInitialVestingPeriodDirectors
P4Y
CY2015 vnda Deferred Revenue Recognized
DeferredRevenueRecognized
-174000
CY2015 vnda Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vesting Period One
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestingPeriodOne
P4Y
CY2015 vnda Defined Contribution Plan Vesting Period
DefinedContributionPlanVestingPeriod
P4Y
CY2015 vnda Option Awards Vesting Period After Completion Of One Year Of Service
OptionAwardsVestingPeriodAfterCompletionOfOneYearOfService
P3Y
CY2015 vnda Increase Decrease In Accrued Government And Other Rebates
IncreaseDecreaseInAccruedGovernmentAndOtherRebates
35055000
CY2015 vnda Effective Income Tax Rate Reconciliation Tax Credits Orphan Drug
EffectiveIncomeTaxRateReconciliationTaxCreditsOrphanDrug
0.016 pure
CY2014Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.79
CY2014Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.79
CY2014Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-26578000
CY2014Q1 us-gaap Revenues
Revenues
9143000
CY2014Q1 us-gaap Net Income Loss
NetIncomeLoss
-26533000
CY2014Q1 us-gaap Gross Profit
GrossProfit
9143000
CY2015Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.24
CY2015Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-10293000
CY2015Q1 us-gaap Revenues
Revenues
22150000
CY2015Q1 us-gaap Net Income Loss
NetIncomeLoss
-10221000
CY2015Q1 us-gaap Gross Profit
GrossProfit
17135000
CY2014Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.64
CY2014Q2 us-gaap Revenues
Revenues
10862000
CY2014Q2 us-gaap Net Income Loss
NetIncomeLoss
-21575000
CY2014Q2 us-gaap Gross Profit
GrossProfit
10664000
CY2015Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.13
CY2015Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-5458000
CY2015Q2 us-gaap Revenues
Revenues
27582000
CY2015Q2 us-gaap Net Income Loss
NetIncomeLoss
-5386000
CY2015Q2 us-gaap Gross Profit
GrossProfit
21816000
CY2014Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.04
CY2014Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.04
CY2014Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-1448000
CY2014Q3 us-gaap Revenues
Revenues
14782000
CY2014Q3 us-gaap Net Income Loss
NetIncomeLoss
-1426000
CY2014Q3 us-gaap Gross Profit
GrossProfit
14079000
CY2015Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.22
CY2015Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-9541000
CY2015Q3 us-gaap Revenues
Revenues
28344000
CY2015Q3 us-gaap Net Income Loss
NetIncomeLoss
-9461000
CY2015Q3 us-gaap Gross Profit
GrossProfit
21834000
CY2014Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.85
CY2014Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.77
CY2014Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
69693000
CY2014Q4 us-gaap Revenues
Revenues
15370000
CY2014Q4 us-gaap Gain Loss Related To Litigation Settlement
GainLossRelatedToLitigationSettlement
77616000
CY2014Q4 us-gaap Net Income Loss
NetIncomeLoss
69719000
CY2014Q4 us-gaap Gross Profit
GrossProfit
14688000
CY2015Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.35
CY2015Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-14893000
CY2015Q4 us-gaap Revenues
Revenues
31849000
CY2015Q4 us-gaap Net Income Loss
NetIncomeLoss
-14798000
CY2015Q4 us-gaap Gross Profit
GrossProfit
25678000

Files In Submission

Name View Source Status
0001193125-16-461076-index-headers.html Edgar Link pending
0001193125-16-461076-index.html Edgar Link pending
0001193125-16-461076.txt Edgar Link pending
0001193125-16-461076-xbrl.zip Edgar Link pending
d97997d10k.htm Edgar Link pending
d97997dex1033.htm Edgar Link pending
d97997dex1034.htm Edgar Link pending
d97997dex1035.htm Edgar Link pending
d97997dex211.htm Edgar Link pending
d97997dex231.htm Edgar Link pending
d97997dex311.htm Edgar Link pending
d97997dex312.htm Edgar Link pending
d97997dex321.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
g97997g33p87.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R76.htm Edgar Link pending
R77.htm Edgar Link pending
R78.htm Edgar Link pending
R79.htm Edgar Link pending
R8.htm Edgar Link pending
R80.htm Edgar Link pending
R81.htm Edgar Link pending
R82.htm Edgar Link pending
R83.htm Edgar Link pending
R84.htm Edgar Link pending
R85.htm Edgar Link pending
R86.htm Edgar Link pending
R87.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
vnda-20151231.xml Edgar Link completed
vnda-20151231.xsd Edgar Link pending
vnda-20151231_cal.xml Edgar Link unprocessable
vnda-20151231_def.xml Edgar Link unprocessable
vnda-20151231_lab.xml Edgar Link unprocessable
vnda-20151231_pre.xml Edgar Link unprocessable